Two cases of cornea verticillata after treatment with vandetanib (i.e., a dual anti-EGFR and vascular endothelial growth factor receptor 2 (VEGFR2) tyrosine kinase inhibitor) for medullary thyroid carcinoma were reported [43]. The gene discussed is EGFR; the disease is medullary thyroid gland carcinoma.